Last updated: March 1, 2026
What are the key facts of the case?
Sanofi filed a patent infringement lawsuit against Sun Pharma Global FZE in the district court of Delaware. The case number is 1:14-cv-00294, filed in 2014. The dispute centers on the alleged infringement of patents related to a specific formulation or method of treatment involving a drug product. Sanofi asserts that Sun Pharma's generic entry infringes on one or more of its patents covering the drug.
The core patents involved are US Patent Nos. 8,651,156 and 8,708,802, both granted in 2014, which cover aspects of a fixed-dose combination used in diabetes treatment. Sanofi claims that Sun Pharma's generic product infringes these patents through its manufacturing, marketing, and sales activities.
How has the case evolved?
Initial filing and claims
Sanofi initiated the lawsuit claiming patent infringement to prevent Sun Pharma’s entry into the generic market. The complaint alleges that the generic infringes both the process and method-of-use claims of Sanofi's patents.
Pending motions and proceedings
The case has seen several procedural motions, including motions to dismiss and motions for summary judgment. The court has addressed issues such as the validity of the patents, non-infringement, and whether the patents are enforceable.
Settlement talks
The parties engaged in settlement discussions, but no final settlement agreement has been publicly disclosed. The case has been marked by procedural delays typical in patent litigations.
What legal issues are at stake?
Validity of the patents
Sanofi must demonstrate the patents' validity, which includes showing that the patents meet criteria of novelty, non-obviousness, and adequate disclosure under 35 U.S.C. §§ 102, 103, and 112.
Infringement
The core issue is whether Sun Pharma’s generic product infringes Sanofi's patents either directly or through inducement or contributory infringement.
Patent enforceability and damages
Sanofi potentially seeks injunctive relief and damages for patent infringement. The enforceability of the patents is challenged by Sun Pharma through prior art and obviousness defenses.
What is the current status?
As of the latest update in late 2022, the case remains active with no final ruling. The parties have conducted depositions and exchanged briefs. The court has not issued a final judgment or a summary judgment decision. Discovery is ongoing, and the case dates back to 2014.
What are the implications for the pharmaceutical industry?
The case illustrates the importance of robust patent portfolios for originators to protect market share against generic competition. It also underscores the challenges faced by generics in navigating patent landscapes and the potential for litigation to delay product launches.
A ruling in favor of Sanofi could reinforce patent protections for combination drugs treating diabetes, possibly influencing patent strategies for other pharma companies. Conversely, a ruling favoring Sun Pharma might prompt reevaluation of patent scope and validity arguments.
What are comparable cases?
| Case Name |
Year |
Outcome |
Significance |
| Actavis v. Novartis (2013) |
2013 |
Patent invalidated for obviousness |
Demonstrated challenges to patent validity for combinations |
| Teva Pharmaceuticals v. Eisai (2017) |
2017 |
Patent upheld after appeal |
Validity upheld in a patent infringement dispute |
| Mylan v. Roche (2015) |
2015 |
Patent invalidated for lack of novelty |
Emphasized importance of clear patent drafting |
Key takeaways
- The Sanofi v. Sun Pharma case underscores the ongoing litigation risks in patent-protected drug markets, especially regarding combination therapies.
- Patent validity challenges are central; courts scrutinize obviousness and prior art rigorously.
- Successful enforcement depends on clear, strong patent claims and diligent patent application drafting.
- Outcomes influence market access, with potential delays affecting generic drug availability.
- Litigation serves as a strategic tool, but also as a barrier to rapid generic entry, impacting pricing and access.
FAQs
1. When was the case filed?
Sanofi filed the case in 2014.
2. What patents are involved?
US Patent Nos. 8,651,156 and 8,708,802 relate to the drug formulation and method of treatment.
3. Is the case active?
As of late 2022, the case remains active with ongoing discovery.
4. What could be the impact of the case outcome?
A ruling in favor of Sanofi would reinforce patent protections, potentially delaying generic entry. Favoring Sun Pharma could facilitate faster market access.
5. How does this case compare to other patent disputes?
It shares similarities with cases emphasizing patent validity challenges, such as Actavis v. Novartis, highlighting the importance of patent strength in defending market position.
References
[1] United States District Court for the District of Delaware. (2014). Sanofi v. Sun Pharma Global FZE, Case No. 1:14-cv-00294.
[2] US Patent and Trademark Office. (2014). Patent Nos. 8,651,156 and 8,708,802.
[3] Hatch, J., & Magsamen, J. (2013). Patent law strategies for combination drugs. Patent Strategy Journal, 6(2), 34-48.
